All Pharma News
BrainStorm Cell Therapeutics Publishes NurOwn`s® Biomarker Data

BrainStorm Cell Therapeutics Publishes NurOwn`s® Biomarker Data
PR NEWSWIRE
10 Apr 2024
Share Share
BrainStorm Cell Therapeutics to Unveil Phase 3b NurOwn® Trial Design

BrainStorm Cell Therapeutics to Unveil Phase 3b NurOwn® Trial Design
PR NEWSWIRE
27 Feb 2024
Share Share
BrainStorm Cell Submits SPA Request to FDA for Phase 3b Trial of NurOwn

BrainStorm Cell Submits SPA Request to FDA for Phase 3b Trial of NurOwn
PR NEWSWIRE
23 Feb 2024
Share Share
BrainStorm Granted Patents for Allogeneic Exosome Platform-Product

BrainStorm Granted Patents for Allogeneic Exosome Platform-Product
PR NEWSWIRE
26 Dec 2023
Share Share
BrainStorm Cell Therapeutics Announces Outcome of FDA Meeting on NurOwn® in ALS

BrainStorm Cell Therapeutics Announces Outcome of FDA Meeting on NurOwn® in ALS
PR NEWSWIRE
07 Dec 2023
Share Share
BrainStorm Cell Therapeutics Announces In-Person Meeting with the FDA

BrainStorm Cell Therapeutics Announces In-Person Meeting with the FDA
PR NEWSWIRE
20 Nov 2023
Share Share
BrainStorm Cell Therapeutics to Present at 6th Annual ALS Research Symposia

BrainStorm Cell Therapeutics to Present at 6th Annual ALS Research Symposia
PR NEWSWIRE
17 Nov 2023
Share Share
BrainStorm lays off 30%, details bid to reach ALS market

BrainStorm lays off 30%, details bid to reach ALS market
Nick Paul Taylor FIERCE BIOTECH
24 Oct 2023
Share Share
BrainStorm to Meet with FDA to Discuss Development Plan for NurOwn

BrainStorm to Meet with FDA to Discuss Development Plan for NurOwn
PR NEWSWIRE
18 Oct 2023
Share Share
BrainStorm eyes FDA meeting to find path for rejected drug

BrainStorm eyes FDA meeting to find path for rejected drug
James Waldron FIERCE BIOTECH
18 Oct 2023
Share Share